AZD 1305
Alternative Names: AZD1305Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Antiarrhythmics
- Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Atrial fibrillation; Atrial flutter; Left ventricular dysfunction
Most Recent Events
- 28 Jan 2010 Discontinued - Phase-I for Arrhythmias in Germany (PO)
- 28 Jan 2010 Discontinued - Phase-I for Arrhythmias in Japan (IV)
- 28 Jan 2010 Discontinued - Phase-I for Arrhythmias in United Kingdom (PO)